Researchers in Australia have developed a drug that could revolutionize treatment for millions of diabetes patients around the world.

Scientists in the U.S., China and Australia are designing treatments that imitate the body’s natural response to changing blood glucose, or sugar, levels and respond instantly.

The Australian team is handling one of several research projects that have developed different types of so-called ‘smart insulins,’ which sits in the body of a diabetes patient and is activated only when it is needed.

The aim is to keep glucose levels within a safe range, avoiding excessively high blood glucose, which is called hyperglycaemia, and excessively low blood sugar levels, known as hypoglycaemia.

The new treatments are not cures for diabetes but could ease the burden on patients.

Australian researchers say their new insulin delivery method would offer one injection every three days. Patients currently have to administer synthetic insulin up to 10 times a day.

Christoph Hagemeyer, a professor at the Australian Center for Blood Diseases at Monash University and a lead researcher in the study, told Australian Broadcasting Corp. Tuesday how the technology works.

“Smart insulin is responding to sugar levels in the blood,” he said. “In our case we are not actually making the insulin molecule smart, but we are loading the insulin onto a nanoparticle, which has a built-in mechanism that it changes its charge from positive to negative when the sugar levels go up. And that is the trick how we can ensure that there is enough insulin onboard and it is released in a smart manner.”

Insulin is a type of hormone that lowers the level of glucose in the blood. Glucose is a type of sugar from food that gives people energy.

Diabetes affects glucose levels in the blood and is normally split into type 1 and type 2, the most common. Patients have a heightened risk of heart attack, stroke, and kidney failure.

Monash University in Melbourne is part of a global effort to develop different types of smart insulins. It includes teams at Stanford University in the United States and Zhejiang University in China. Each project aims to develop smart insulin to act faster and more accurately to help patients with diabetes and to start trials as soon as possible.

The World Health Organization has estimated that about 422 million people around the world have diabetes and that 1.5 million deaths are directly attributed to the chronic disease each year.